(Source: ASHP - American Society of Health-System Pharmacists) BETHESDA, MD 18 Sep 2015- FDA and Actavis on September 17 announced the approval of cariprazine oral capsules for the treatment of schizophrenia and acute manic or mixed episodes of bipolar disorder I in adults. The atypical antipsychotic is expected to be commercially available in the United States during the first quarter of 2016, according to an Actavis spokesman. The drug will be marketed as Vraylar. A boxed warning in the labeling for cariprazine...
↧
